Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?
12:40pm, Tuesday, 14'th Apr 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CSL Limited Sponsored ADR (CSLLY) and Acadia Pharmaceuticals (ACAD). But which of these two stocks i
Mark Schneyer Sells 2,709 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock
04:54am, Thursday, 09'th Apr 2026
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD - Get Free Report) EVP Mark Schneyer sold 2,709 shares of the firm's stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of
Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Wednesday, 08'th Apr 2026
Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Brokerages
02:27am, Saturday, 28'th Mar 2026
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty brokerages that are currently covering the company, Ma
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
12:32pm, Friday, 27'th Mar 2026
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback
02:53pm, Wednesday, 25'th Mar 2026
Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more attractive risk-reward profile for investors. The
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback
10:51am, Wednesday, 25'th Mar 2026
Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more...
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year
02:02am, Thursday, 19'th Mar 2026
ACADIA Pharmaceuticals (NASDAQ: ACAD) executives discussed upcoming clinical readouts and pipeline priorities during the company's virtual CNS conference, with a focus on remlifanserin (formerly ACP-2
ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by First Trust Advisors LP
04:32am, Friday, 13'th Mar 2026
First Trust Advisors LP lessened its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 20.2% in the undefined quarter, according to the company in its most recent filing with the Securities and E
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
04:05pm, Thursday, 12'th Mar 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:
JAZZ or ACAD: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 09'th Mar 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Acadia Pharmaceuticals (ACAD). But which of these two stocks o
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)
06:10am, Thursday, 05'th Mar 2026
Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
09:05am, Wednesday, 04'th Mar 2026
Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
04:05pm, Tuesday, 03'rd Mar 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on
